Archive for the ‘Hypogonadism’ Category

The report on Testosterone Cypionate, gives an in-depth analysis of Global Testosterone Cypionate Market based on aspects that are very important for the market study. Factors like production, market share, revenue rate, regions and key players define a market study start to end. This report gives an overview of market valued in the year 2019 and its growth in the coming years till 2026. The report is based on the in-depth view of Testosterone Cypionate industry on the basis of market growth, market size, development plans and opportunities offered by the global Testosterone Cypionate market. The energetic aspects studied in this report include SWOT analysis, feasibility and forecast information.

Request a sample of Testosterone Cypionate Market report @ https://www.orbispharmareports.com/sample-request/41768

For the consumers to gain the in-depth analysis of the global Testosterone Cypionate market and further growth of the market, the report offers significant statistics and information. Testosterone Cypionate report studies the current state of the market to analyze the future opportunities and risks. Testosterone Cypionate report provides a 360-degree global market state. Primarily, the report delivers Testosterone Cypionate introduction, overview, market objectives, market definition, scope, and market size valuation.

Major companies of this report:

PfizerTevaCiplaSun PharmaceuticalHikma PharmaceuticalsPerrigo

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/41768

Moreover, the report provides historical information with future forecast over the forecast period. Some of the important aspects analyzed in the report includes market share, production, key regions, revenue rate as well as key players. This Testosterone Cypionate report also provides the readers with detailed figures at which the Testosterone Cypionate market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the Testosterone Cypionate is expected to mount and major factors driving markets growth. The study on global Testosterone Cypionate market, offers deep insights about the Testosterone Cypionate market covering all the crucial aspects of the market.

Testosterone Cypionate Market Segmentation by Type:

200 mg/mL100 mg/mL

Testosterone Cypionate Market Segmentation by Application:

Primary hypogonadismHypogonadotropic hypogonadismLate-onset hypogonadism

In addition, the report include deep dive analysis of the market, which is one of the most important features of the market. Furthermore, the need for making an impact is likely to boost the demand for the experts which are working in the market. Moreover, an in depth analysis of the competitors is also done to have an estimate for the market. The Testosterone Cypionate market has its impact all over the globe. On global level Testosterone Cypionate industry is segmented on the basis of product type, applications, and regions. It also focusses on market dynamics, Testosterone Cypionate growth drivers, developing market segments and the market growth curve is offered based on past, present and future market data. The industry plans, news, and policies are presented at a global and regional level.

Place a purchase order of this report @ https://www.orbispharmareports.com/buy-now/41768

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

See the rest here:
Global Testosterone Cypionate Market (Covid-19 Impact) Expected to Witness a Sustainable Growth over 2026 - Market Research Correspondent

Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist

ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience , Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia. This approval, which was secured by the Company's ZolpiMist sublicensee SUDA Pharmaceuticals Ltd ("SUDA"), enables near-term commercialization of ZolpiMist in Australia. SUDA (ASX:SUD) is a publicly-listed drug delivery company focused on oro-mucosal administration and is headquartered in Perth, Western Australia.

With this approval by Australia's TGA, ZolpiMist will be included on the Australian Register of Therapeutic Goods and can now be commercialized and supplied within Australia. Further, this approval will assist SUDA's current ZolpiMist sublicensees, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Singapore and MTP Korea, in their submissions in their respective territories.

On March 9, 2010 Aytu BioScience announced a global distribution agreement for ZolpiMist with SUDA whereby the Company assumed a milestone and royalty-based licensing agreement with SUDA. As specified in the companies' global licensing agreement, SUDA will pay Aytu a portion of each upfront and milestone payment received from sublicensees, and Aytu will receive ongoing royalty payments on sales generated by SUDA's sublicensees as ZolpiMist is launched in each territory.

Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, "We congratulate the SUDA team for obtaining TGA approval for ZolpiMist and look forward to SUDA and their partners moving ZolpiMist closer to commercialization in Australia and elsewhere. This is an exciting time for SUDA and represents an important milestone for Aytu as we move closer to realizing ex-US licensing revenue for ZolpiMist."

Dr. Michael Baker, Chief Executive Officer and Managing Director of SUDA, commented, "The TGA submission was a combined effort by SUDA's technical team as well as our regulatory consultant, Pharma To Market. Obtaining the approval indicates the calibre of our staff and is also a key benefit to our partners for ZolpiMist. We are delighted by the outcome and look forward to seeing the commencement of commercial sales in the foreseeable future."

The global sleep aid market is currently estimated at almost $50 billion in annual revenue, and annual revenue is estimated to reach nearly $80 billion in 2022.

About Aytu BioScience, Inc.Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distributes a COVID-19 IgG/IgM rapid test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma.

Aytu also operates a subsidiary focused on consumer health, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human marketing and sales platform.

Aytu's strategy is to continue building its portfolio of revenue-generating Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.

About SUDA Pharmaceuticals Ltd SUDA Pharmaceuticals Ltd (ASX:SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer. For more information, visit http://www.sudapharma.com

Forward-Looking StatementThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, the regulatory and commercial risks associated with introducing the COVID-19 rapid test, the effectiveness of the COVID-19 rapid rest, market acceptance of the National Cancer Institute or other independently conducted studies' testing results, the regulatory, clinical, and commercial risks associated with the investigational Healight device, effects of the business combination of Aytu and the Commercial Portfolio and the merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, including the risks associated with ZolpiMist's commercial success in Australia and elsewhere, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for Investors:James CarbonaraHayden IR(646) 755-7412james@haydenir.com

SOURCE: Aytu BioScience, Inc.

View source version on accesswire.com:https://www.accesswire.com/599574/Aytu-BioScience-Announces-Regulatory-Approval-of-ZolpiMistR-by-Australian-Therapeutic-Goods-Administration

Follow this link:
Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - BioSpace

Andropause or male menopause has to do with the declining hormonal levels in older men. Read on to know the symptoms, causes and treatment of this condition.

We often talk about how women suffer from menopause and how it affects their health. But did you know that men also experience menopause? If scientific studies are to be believed, men also go through hormonal changes after the age of 50. However, it is very different from what women go through. Male menopause is a common term used for andropause, which refers to the decline in mens testosterone levels.

In andropause, the production of testosterone and other hormones decline in men. Testosterone is a hormone that leads to changes during puberty, manages your physical and mental health, maintains muscle mass, fuels sex-drive and other important functions in the body. The condition is also known as testosterone deficiency and late-onset hypogonadism. It is often associated with hypogonadism, which shows similar symptoms to this condition.

Symptoms

As per studies, this condition can cause a variety of symptoms and complications in the body.

- low energy levels

- depression or sadness

- feeling less motivated

- not able to focus on things

- insomnia

- development of breasts

- erectile dysfunction

- infertility

- decreased libido

- reduced bone density and muscle mass

- hair loss

- hot flashes

Treatment

Your doctor might take a blood sample to test your testosterone levels. However, in most cases, the symptoms are manageable without treatment. Making healthy lifestyle choices can help you alleviate the symptoms. So, eating healthy, regular exercise, adequate sleep, and less stress are some lifestyle changes that may help.

In case youre experiencing depression, your doctor may prescribe antidepressants, therapy and above-mentioned lifestyle changes.

Male VS Female Menopause

This has been a controversial topic for several years. According to Mayo Clinic, male menopause is nothing like female menopause. Female menopause is a natural part of ageing for women, whereas, male menopause doesnt even affect some older men. Due to the significant differences between the two conditions, doctors prefer calling it andropause or late-onset hypogonadism.

x Your comment has been submitted to the moderation queue

See the original post:
What is Male Menopause? Heres everything you need to know about andropause - PINKVILLA

According to the latest report by IMARC Group, titled North America Hormone Replacement (HRT) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025, the hormone replacement market in North America reached a value of US$ 502.6 Million in 2019. Hormone replacement therapy (HRT) is the most effective treatment that is used to supplement the hormones present in low levels in the human body. This treatment is usually suggested for patients who are experiencing growth hormone deficiency, women nearing menopause and elderly who are suffering from hypogonadism.

Request Free Sample Report: https://www.imarcgroup.com/north-america-hormone-replacement-therapy-market/requestsample

HRT is considered to be useful in treating the symptoms of menopause like night sweats, hot flashes, vaginal dryness and sexual function. It also aids in minimizing the risk of cardiovascular diseases, colorectal cancer, vasomotor symptoms and osteoporosis. Apart from this, countries in the North America region support the medical transition. For instance, the Canadian Bar Association favors this process of altering primary or secondary sex characteristics through hormone therapy or a variety of surgical procedures, which in turn is boosting its demand across the region. Moreover, technological advancements, coupled with the increasing investments in research and development (R&D) activities to enhance the quality and efficiency of hormone replacement therapies, are further providing a thrust to the market growth. Looking forward, IMARC Group, expects the market to reach levels worth US$ 5.0 million by 2025 exhibiting a CAGR of 5.2% during 2020-2025.

Market Breakup by End-User:

Market Breakup by Regions:

Ask Analyst and Download Full Report with List of Figure: https://bit.ly/3ioPCze

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc.. Click request free sample report. We deliver report with-in 24 hours.

Source: steemit

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group30 N Gould St Ste RSheridan, WY 82801, USAEmail: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

See the article here:
North America Hormone Replacement Therapy Market: Demand, Share, Size, Industry Trends, Analysis and Forecast during 2020-2025 - Jewish Life News

According to the latest report by IMARC Group, titled North America Hormone Replacement (HRT) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025, the hormone replacement market in North America reached a value of US$ 502.6 Million in 2019. Hormone replacement therapy (HRT) is the most effective treatment that is used to supplement the hormones present in low levels in the human body. This treatment is usually suggested for patients who are experiencing growth hormone deficiency, women nearing menopause and elderly who are suffering from hypogonadism.

Request Free Sample Report: https://www.imarcgroup.com/north-america-hormone-replacement-therapy-market/requestsample

HRT is considered to be useful in treating the symptoms of menopause like night sweats, hot flashes, vaginal dryness and sexual function. It also aids in minimizing the risk of cardiovascular diseases, colorectal cancer, vasomotor symptoms and osteoporosis. Apart from this, countries in the North America region support the medical transition. For instance, the Canadian Bar Association favors this process of altering primary or secondary sex characteristics through hormone therapy or a variety of surgical procedures, which in turn is boosting its demand across the region. Moreover, technological advancements, coupled with the increasing investments in research and development (R&D) activities to enhance the quality and efficiency of hormone replacement therapies, are further providing a thrust to the market growth. Looking forward, IMARC Group, expects the market to reach levels worth US$ 5.0 million by 2025 exhibiting a CAGR of 5.2% during 2020-2025.

Market Breakup by End-User:

Market Breakup by Regions:

Ask Analyst and Download Full Report with List of Figure: https://bit.ly/3ioPCze

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc.. Click request free sample report. We deliver report with-in 24 hours.

Source: steemit

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group30 N Gould St Ste RSheridan, WY 82801, USAEmail: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

View original post here:
North America Hormone Replacement Therapy Market: Share, Industry Trends, Price, Size, Demand and Forecast to 2020-2025 - 3rd Watch News

Analytical Research has added a new report to their increasing litany of reports titled Testosterone undecanoate Market Report. The new study encompasses valuable insights using a variety of graphs, tables and figures that explores opportunities, trends and drivers surrounding the Testosterone undecanoate industry.

HNY Research projects that the Testosterone undecanoate market size will grow from XXX in 2019 to XXX by 2025, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025.

Download PDF Sample of Testosterone undecanoate Market report @https://www.arcognizance.com/enquiry-sample/997770

By Market Players:Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, Cipla, Zhejiang Xianju Pharmaceutical, Zhejiang Medicine Co.

By ApplicationPrimary hypogonadism, Hypogonadotropic hypogonadism, Late-onset hypogonadism

By TypeInjection, Oral

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Brief about Testosterone undecanoate Market Report with [emailprotected] https://www.arcognizance.com/report/2020-2025-global-and-regional-testosterone-undecanoate-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

Points Covered in The Report:The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements.The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to PurchaseTo gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.Assess the production processes, major issues, and solutions to mitigate the development risk.To understand the most affecting driving and restraining forces in the market and its impact in the global market.Learn about the market strategies that are being adopted by leading respective organizations.To understand the future outlook and prospects for the market.Besides the standard structure reports, we also provide custom research according to specific requirements.

Single User License Copy and other purchase [emailprotected] https://www.arcognizance.com/purchase/997770

Table of Content

Chapter One: Industry Overview

Chapter Two: Major Segmentation (Classification, Application and etc.) Analysis

Chapter Three: Production Market Analysis

Chapter Four: Sales Market Analysis

Chapter Five: Consumption Market Analysis

Chapter Six: Production, Sales and Consumption Market Comparison Analysis

Chapter Seven: Major Manufacturers Production and Sales Market Comparison Analysis

Chapter Eight: Competition Analysis by Players

Chapter Nine: Marketing Channel Analysis

Chapter Ten: New Project Investment Feasibility Analysis

Chapter Eleven: Manufacturing Cost Analysis

Chapter Twelve: Industrial Chain, Sourcing Strategy and Downstream Buyers

List of Table and Figure

Figure Product PictureTable 2014-2019 Major Types Market Sales Volume And Market ShareFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateTable 2014-2019 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross And Gross MarginFigure 2014-2019 Capacity, Production And Growth RateFigure 2014-2019 Capacity, Production And Capacity Utilization Rate continued

If you have any special requirements, please let us know and we will offer you the report as you want.

Other Trending Report:

Global Shale Oil Market Status and Future Forecast 2015-2025 @ https://www.marketwatch.com/press-release/shale-oil-market-size-study-with-covid-19-impact-2020-share-global-industry-analysis-growth-trends-segmentation-and-forecast-to-2025-2020-06-30

Note: Our report does take into account the impact of corona virus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

About us: Analytical Research Cognizance (ARC) is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential. ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448[emailprotected]

Originally posted here:
Testosterone undecanoate Market 2020 | What Will Be the Market Size and the Growth Rate Analysis by 2025? - Cole of Duty

Human chorionic gonadotropin (hCG) hails from the group of gonadotropin hormones and is normally delivered by the placenta. hCG hormone plays an essential job after the development of the embryo, and subsequently has increased huge footing throughout the years for the treatment of fruitlessness in ladies and men.

Sample Link Here: https://www.globalinforeports.com/request-sample/1070128

By Therapeutic Area

By Technology

By End User

Growth in the frequency of male hypogonadism among the aged populace is the key factor driving the market development. Moreover, increment in footing picked up by hCG among healthcare experts and patients would enhance the market development. However, alerts and admonitions gave by the FDA relating to the symptoms of hCG treatment is anticipated to hamper the development of the market.

North America was the significant income contributor in 2017 and is foreseen to keep up its predominance all through the figure time frame.

Purchase Link Here: https://www.globalinforeports.com/checkout/1070128

Read more here:
Advancements in treatments in healthcare is boosting the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle

With this new market research report namelyGlobal Hormone Replacement Therapy Market Growth 2020-2025we are accomplishing our aim of providing our clients an in-depth analysis of the global market. The report features a comprehensive analysis and enlightens market dynamics that provide a holistic picture of the global Hormone Replacement Therapy industry. The report offers knowledge about the industry competitors, growth potential, potentially disruptive trends, industry product innovations, market size value/volume (regional/country level, industry segments), and market share of top players/products. Growth figures are demonstrated between the forecast time-span using industrial facts and figures. The study comprises an analysis of market growth, consumption volume, market trends, and business price structures throughout the forecast amount from 2020 to 2025.

Some of the major Hormone Replacement Therapy market players are:Eli Lilly, Abbott, Pfizer, Novo Nordisk, Merck KGaA, AbbVie, Teva, Mylan, Novartis, Bayer, Roche, ANI Pharmaceuticals, Ipsen, TherapeuticsMD, Endo International,

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/62589

Recent Industry Trend:

The report shows the profiles of various prominent players in the global Hormone Replacement Therapy market. Different strategies implemented by these vendors have been analyzed and studied to gain a competitive edge, create unique product portfolios, and increase their market share. The report also throws light on major global industry vendors including essential vendors consist of both new and well-known players. Different strategies implemented by these vendors have been analyzed. The key insights have been covered to deliver a realistic overview of the industry, covering global Hormone Replacement Therapy market manufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc.

Following are the major regions considered for the analysis of the market: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Most important types of products covered in this report are: Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone

Most widely used downstream fields of market covered in this report are: Menopause, Hypothyroidism, Growth Hormone Deficiency, Male Hypogonadism, Other

Major Aspects Widely Described In The Report Are:

All segments of the global Hormone Replacement Therapy market have been covers in this study. The report highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion. The research report segments the geographical spectrum of this industry. The report provides market dynamics scenarios, along with growth opportunities of the market in the years to come.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/62589/global-hormone-replacement-therapy-market-growth-2020-2025

What Insights Does The Hormone Replacement Therapy Market Report Provide To The Readers?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:[emailprotected]Web:www.marketsandresearch.biz

See the rest here:
Global Hormone Replacement Therapy Market 2020 Research by Business Analysis, Growth Strategy and Industry Development to 2025 - Cole of Duty

Testosterone therapy ads promise to help aging men recapture their vitality, decrease body fat and enhance libido. But hormone treatments while medically necessary for some men arent meant to be a fountain of youth, and experts warn more research is needed to determine if such therapy could boost heart disease risks.

Testosterone levels naturally decline in most men as they age. This decline is generally mild, and symptoms often are nonspecific, such as low energy, reduced muscle mass and reduced vigor. Roughly 20% of men over the age of 60 have experienced a drop in testosterone levels, though this gradual decline can begin as early as the mid-30s.

While that can be frustrating, experts say its not a clinical indication of a need for testosterone therapy, nor is there any evidence that therapy is effective for treating those symptoms. The Food and Drug Administration has limited approval of testosterone therapy to the treatment of organic hypogonadism, a dramatic drop in testosterone caused by disease or injury of the hypothalamus, pituitary gland or the testes.

If testosterone therapy is used appropriately in men with organic hypogonadism, then there is no controversy, said Dr. Shehzad Basaria, associate director of Mens Health: Aging and Metabolism at Brigham and Womens Hospital in Boston. The condition causes specific symptoms such as decreased sexual desire, breast enlargement, testicular atrophy and hot flashes.

But in middle-aged and aging men who have a slightly lower testosterone level and nonspecific symptoms due to aging or obesity, testosterone therapy is not indicated. Similarly, testosterone is not a rejuvenation drug, said Basaria, an associate professor of medicine at Harvard Medical School. The majority of patients seen in our clinics have symptoms such as fatigue, weight gain, muscle loss or feeling sad. These symptoms are common and nonspecific, and testosterone therapy is generally not indicated in such clinical scenarios.

Over the past two decades, intense direct-to-consumer marketing of hormone therapy for aging men, much of it via television ads, has more than doubled its off-label use. Its a trend experts warn is medically unwarranted and potentially harmful.

The American College of Physicians, which issued new guidelines in January, recommends against prescribing testosterone therapy to boost energy, vitality or physical function, but supports its use for men experiencing sexual dysfunction. The recommendation calls for discussing potential benefits and risks with the patient and discontinuing treatment after one year if there is no improvement.

I think one of the biggest concerns about testosterone therapy is whether it is really needed, said Dr. Robert Eckel, professor of medicine and an endocrinologist at the University of Colorado School of Medicine in Aurora, Colorado. Erectile dysfunction is a common problem as men age, but there can be other reasons for this, such as vascular disease or nerve damage, which is more common in patients with diabetes. It is not necessarily an indication for treatment with testosterone therapy. The patient must be properly evaluated.

The FDA warns against prescribing testosterone therapy for age-related hormonal decreases or anything other than a medical diagnosis of hypogonadism. Since 2015, it has required testosterone product labels to warn of a possible increased risk of heart attacks and stroke.

But research about that association so far is unclear, Basaria said

Some studies have reported higher cardiovascular risk with testosterone use but there are an equal number of studies showing that it does not increase cardiovascular risk, he said. This discrepancy exists because no study published to date has been powered to assess cardiovascular events as the primary outcome.

Eckel, president of medicine and science for the American Diabetes Association and a past president of the American Heart Association, agreed. The cardiovascular disease outcome story is not convincing one way or another. I think to make a strong statement here would be a mistake.

See the article here:
No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - The Gardner News

Latest Research Report on Global Human Chorionic Gonadotropin (hCG) Market Forecast to 2027 Covid-19 Impact and Global Analysis by Technology (Natural Source Extraction, Recombinant Technology); Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, Others); End User (Fertility Clinics, Research Institutions, Others).The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Human Chorionic Gonadotropin (hCG) market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

Request Sample Copy of Human Chorionic Gonadotropin (hCG) Market at: https://www.theinsightpartners.com/sample/TIPRE00004577/

Some of the key players profiled in the study are Merck & Co, Inc, Ferring B.V, Fresenius Kabi AG, Cigna, Sun Pharmaceutical Industries Ltd, Lee BioSolutions Inc, Sanzyme, Scrippslabs , Lupin AB, Prospec-Tany Technogene Ltd, etc.

Key Benefits

Human Chorionic Gonadotropin (hCG) Market Study: An Introduction to Fundamental Charting

Human chorionic gonadotropin also known as hCG. This hormone plays a different role in both male & female sexual development. In female, the hCG mostly used to identify defect and confirm pregnancy and it is made from placenta during pregnancy which nourishes the egg after it has been fertilize. In male, especially young boys it used to increase sperm count. The hCG is administrated in body through the injection under skin into muscle. The human chorionic gonadotropin level can be Identify with the help of blood and urine test.

The human chorionic gonadotropin (hCG) market is expected to grow during the forecast period due to changing life style and increase stress level in life which affects the fertility related disease, rising incidences of male hypogondism among the geriatric population are major key driving factors of the human chronic gonadotropin market. Raising the demands and availability of infertility treatment are likely to create growth opportunities during forecast period.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Human Chorionic Gonadotropin (hCG) market. The researcher provides an extensive analysis of the Human Chorionic Gonadotropin (hCG) market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Human Chorionic Gonadotropin (hCG) industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Human Chorionic Gonadotropin (hCG) market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Human Chorionic Gonadotropin (hCG) market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Promising Regions & Countries Mentioned in The Human Chorionic Gonadotropin (hCG) Market Report:

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00004577/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Visit link:
Human Chorionic Gonadotropin (hCG) Market Insights on Growth Trends, Top Players, Types, Applications and Regional Analysis - Personal Injury Bureau...

A new business intelligence report on Global Male Hypogonadism Therapy market by Player, Region, Type, Application and Sales Channel is designed covering micro level of analysis by manufacturers and key business segments. The Global Male Hypogonadism Therapy market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing.

The research report on Male Hypogonadism Therapy market comprises of an in-depth analysis of this business vertical, while evaluating all the segments of this industry landscape. The report provides with key insights regarding the competitive ambit as well as gross earnings of key market players. Moreover, the information concerning the regional contribution and the competitive landscape of the market is cited in the report.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/6901

The COVID-19 pandemic has compelled various governments to impose strict lockdown which in turn has halted the operations and processes of several firms as well as manufacturing facilities, thereby affecting global economy. Additionally, numerous enterprises across the globe are witnessing scarcity of labor along with insufficient raw materials owing to the disease outbreak, which is estimated to result in modification in the growth of Male Hypogonadism Therapy market in the forthcoming years.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/6901

Emphasizing on the competitive spectrum of Male Hypogonadism Therapy market:

Highlighting the major parts from the Male Hypogonadism Therapy market report:

Elaborating on the regional scope of Male Hypogonadism Therapy market:

Global Male Hypogonadism Therapy Market: Segment Analysis

The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the Male Hypogonadism Therapy market growth.

Global Market: Competitive Landscape

In the competitive analysis section of the report, leading as well as prominent players of the global Male Hypogonadism Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

Other aspects of Male Hypogonadism Therapy market research report:

Key Questions Answered in Global Male Hypogonadism Therapy Market Report: -

The Report Provides The Following Information:

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/6901

See the rest here:
Male Hypogonadism Therapy Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026 - CueReport

Testosterone therapy ads promise to help aging men recapture their vitality, decrease body fat and enhance libido. But hormone treatments while medically necessary for some men arent meant to be a fountain of youth, and experts warn more research is needed to determine if such therapy could boost heart disease risks.

Testosterone levels naturally decline in most men as they age. This decline is generally mild, and symptoms often are nonspecific, such as low energy, reduced muscle mass and reduced vigor. Roughly 20% of men over the age of 60 have experienced a drop in testosterone levels, though this gradual decline can begin as early as the mid-30s.

While that can be frustrating, experts say its not a clinical indication of a need for testosterone therapy, nor is there any evidence that therapy is effective for treating those symptoms. The Food and Drug Administration has limited approval of testosterone therapy to the treatment of organic hypogonadism, a dramatic drop in testosterone caused by disease or injury of the hypothalamus, pituitary gland or the testes.

If testosterone therapy is used appropriately in men with organic hypogonadism, then there is no controversy, said Dr. Shehzad Basaria, associate director of Mens Health: Aging and Metabolism at Brigham and Womens Hospital in Boston. The condition causes specific symptoms such as decreased sexual desire, breast enlargement, testicular atrophy and hot flashes.

But in middle-aged and aging men who have a slightly lower testosterone level and nonspecific symptoms due to aging or obesity, testosterone therapy is not indicated. Similarly, testosterone is not a rejuvenation drug, said Basaria, an associate professor of medicine at Harvard Medical School. The majority of patients seen in our clinics have symptoms such as fatigue, weight gain, muscle loss or feeling sad. These symptoms are common and nonspecific, and testosterone therapy is generally not indicated in such clinical scenarios.

Over the past two decades, intense direct-to-consumer marketing of hormone therapy for aging men, much of it via television ads, has more than doubled its off-label use. Its a trend experts warn is medically unwarranted and potentially harmful.

The American College of Physicians, which issued new guidelines in January, recommends against prescribing testosterone therapy to boost energy, vitality or physical function, but supports its use for men experiencing sexual dysfunction. The recommendation calls for discussing potential benefits and risks with the patient and discontinuing treatment after one year if there is no improvement.

I think one of the biggest concerns about testosterone therapy is whether it is really needed, said Dr. Robert Eckel, professor of medicine and an endocrinologist at the University of Colorado School of Medicine in Aurora, Colorado. Erectile dysfunction is a common problem as men age, but there can be other reasons for this, such as vascular disease or nerve damage, which is more common in patients with diabetes. It is not necessarily an indication for treatment with testosterone therapy. The patient must be properly evaluated.

The FDA warns against prescribing testosterone therapy for age-related hormonal decreases or anything other than a medical diagnosis of hypogonadism. Since 2015, it has required testosterone product labels to warn of a possible increased risk of heart attacks and stroke.

But research about that association so far is unclear, Basaria said

Some studies have reported higher cardiovascular risk with testosterone use but there are an equal number of studies showing that it does not increase cardiovascular risk, he said. This discrepancy exists because no study published to date has been powered to assess cardiovascular events as the primary outcome.

Eckel, president of medicine and science for the American Diabetes Association and a past president of the American Heart Association, agreed. The cardiovascular disease outcome story is not convincing one way or another. I think to make a strong statement here would be a mistake.

See more here:
No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - Lexington Dispatch

The most advanced study released by AMR on the Transdermal Testosterone market comprising key market segments such as Type, Application, Sales, Growth, Comprises details of companies manufacturing field, production volume, capacities, value chain, product specifications, raw material sourcing strategies, concentration rate, organizational structure, and distribution channel.

The COVID-19 outbreak is now traveling around the world, leaving a trail of destruction in its wake. This report discusses the impact of the virus on leading companies in the Transdermal Testosterone sector.

The research is a precise offset bridging both qualitative and quantitative data of Transdermal Testosterone market.

The study provides historical data to compare for evolving Sales, Revenue, Volume, Value of 2014 to 2019 and forecasted till 2026.

It becomes necessary to analyze the competitors progress while operating into the same competing environment, for that purpose, the report provides thorough insights into market competitors marketing strategies which include alliances, acquisitions, ventures, partnerships, as well as product launches, and brand promotions.

Transdermal Testosterone Market with Impact Analysis of COVID-19: Key Major Players areAbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddys Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc..

Sample PDF Copy Instantly in your email box at: https://www.amplemarketreports.com/sample-request/global-transdermal-testosterone-market-1755445.html

Transdermal Testosterone Research objectives

Focuses on the key global Transdermal Testosterone players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis, and development plans in the next few years.

Competitive Structure and analysis of The Transdermal Testosterone Market:

Some of the players have a stellar growth track record for 2014 to 2018, some of these companies have shown tremendous growth by sales and revenue while net income more than doubled in the same period with performing as well as gross margins expanding. The growth in gross margins over the years points to strong pricing power by the company for its products, over and above the increase in the cost of goods sold.

The report further features analysis that contains details of companies manufacturing base, production volume, sizes, value chain, product specifications.

According to AMR, key market segments sales will traverse the $$ mark in the year 2020. Unlike classified segments by Type (Gel, Patch, Solution), by End-Users/Application (Primary hypogonadism, Hypogonadotropic hypogonadism, Late-onset hypogonadism).

2020 report version is the most advanced which is further divided and highlights a new emerging twist of the industry.

Transdermal Testosterone market will increase from $XX million in 2019 to strike $YY million by 2026, with a compound annual growth rate (CAGR) of xx%. The most robust growth is anticipated in Asia-Pacific, where CAGR is presumed to be ##% from 2019 to 2026. This prediction is good news for market players, as there is good potential for them to continue developing alongside the industrys projected growth.

Find out more on growth of Transdermal Testosterone market at: https://www.amplemarketreports.com/report/global-transdermal-testosterone-market-1755445.html

Market players have determined strategies to offer a whole host of new product launches within several markets around the globe. Remarkable models are variant to be launched in eight EMEA markets in Q4 2019 and 2020. Acknowledging all-around exercises some of the players profiles that would be worth reviewing are AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddys Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc..

Although recent years might not be that inspiring as market segments have registered reasonable gains, things could have been better if manufacturers would have plan-driven move earlier. Unlike past, but with a decent estimate, investment cycle continuing to progress in the U.S., many growth opportunities ahead for the companies in 2020, it looks like a good for today but stronger returns can be expected beyond.

Get to know about Discount at: https://www.amplemarketreports.com/discount-request/global-transdermal-testosterone-market-1755445.html

Report Answers Following Questions:

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customization according to specific needs.

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to deliver reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

https://www.amplemarketreports.com

More here:
Emerging Opportunity in Transdermal Testosterone Market with Eminent Key Players and Future Outlook to 2024: AbbVie, Teva, Perrigo, Endo...

Testosterone Gel Industry report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Testosterone Gel industry analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Global Testosterone Gel Industry 2020 Research report is spread across 126 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share questions if any before the purchase on this https://www.orianresearch.com/enquiry-before-buying/1571158

The key players covered in this study

AbbVie

Teva

Perrigo

Endo Pharmaceuticals

Acerus Pharmaceuticals

Lupin

Dr. Reddys Laboratories

Upsher-Smith Laboratories.

This report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Testosterone Gel, revenue and market share, for key manufacturers.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Third by regions, this report focuses on the sales (consumption), production, import and export of Testosterone Gel.

Order a Copy of Global Testosterone Gel Market Report @ https://www.orianresearch.com/checkout/1571158

The Global Testosterone Gel Industry focus on Global major leading industry players, providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out.

Market segment by Type, the product can be split into

0.01

0.0162.

Market segment by Application, split into

Primary hypogonadism

Hypogonadotropic hypogonadism

Late-onset hypogonadism.

Market segment by Regions/Countries, this report covers

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E.

Finally by applications, this report focuses on consumption and growth rate of Testosterone Gel in major applications.

Major Points Covered in Table of Contents:

1. Testosterone Gel Market Overview

2. Market Competition by Manufacturers

3. Production Capacity by Region

4. Global Testosterone Gel Consumption by Regions

5. Production, Revenue, Price Trend by Type

6. Global Testosterone Gel Market Analysis by Application

7. Company Profiles and Key Figures in Testosterone Gel Business

8. Testosterone Gel Manufacturing Cost Analysis

9. Marketing Channel, Distributors and Customers

10. Market Dynamics

11. Production and Supply Forecast

12. Consumption and Demand Fprecast

13. Forecast by Type and by Application (2021-2026)

14. Reseach Finding and Conclusion

15. Methodology and Data Source.

At last, please let us know your requirements and we will offer you the report as you want.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727| UK: +44 020 8144-71-27

View post:
Testosterone Gel Market: 2020 Industry Trends, Size, Growth Predictions, Segmentation, Business Statistics, Top Key Players and 2026 Forecast Research...

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

For detailed insights on enhancing your product footprint, request for a Sample Report herehttps://www.persistencemarketresearch.com/samples/29509

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region.

In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others

For in-depth competitive analysis, Check Pre-Book herehttps://www.persistencemarketresearch.com/checkout/29509

Reasons to Purchase this Report:

Accuracy and QualityOur reports strive to offer superior quality reports based on authentic and accurate findings.Customer SatisfactionWe aim to ensure that our clients research needs are met with customized, top-of-the-line solutions.Unmatched ExpertiseOur analysts and consultants are among the best in their field and promise to deliver excellent market intelligence.360-degree AnalysisWe leave no stone unturned to give clients an exhaustive coverage of the industry.

Our client success stories feature a range of clients fromFortune 500 companiesto fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

About Us :

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources.

Contact Us

Persistence Market ResearchU.S. Sales Office305 Broadway, 7th FloorNew York City, NY 10007+1-646-568-7751United StatesUSA-Canada Toll-Free: 800-961-0353E-mail id-[emailprotected]Website:www.persistencemarketresearch.com

Excerpt from:
Anabolic Steroids Market to Witness Heightened Revenue Growth in the Next Decade - Owned

The global Male Hypogonadism Therapy Market is showing promising signs that can be explored well in the coming days to achieve a notable valuation by the end of 2020. The process would also witness a growth by % CAGR in between 2020 to 2026. The report is expected to consider the time-frame as the forecast period and it would deal with the market accordingly. Growth-inducing factors have been monitored closely in the report to gauge well the progress of the market. Each factor can play a significant role and has been given proper space on the basis of which the market can devise strategies. It has tracked various associated fields as well to get a proper map of how these end user industries are impacting the market and can take the market forward. The report has credibility as it banks on the expertise of adept researchers who fetch numbers from a pool of information and sieve them as per the requirement. In the process, they have gone through the market by having it analyzed on top-down and bottom-up basis.

The major player in global Male Hypogonadism Therapy market includes:

Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD, and more

Get a free sample copy @ https://www.reportsandmarkets.com/sample-request/global-male-hypogonadism-therapy-market-size-status-and-forecast-2020-2026?utm_source=farmersledger&utm_medium=39

The segmentation plays a prominent role in dealing with the growth of the Male Hypogonadism Therapy Market where various types and applications are promoting better understanding of the market. This segmentation has a strong foundation in volume-wise and value-wise data which backs the process of understanding the market scenario with numbers. The market has been combed through properly to get all the factors in line. The report has been enriched interviews as a first hand method of getting data. These interviews include chats with top market players, market analysts, distributors, people in the field of research and development and others owing to which the reliability of the report has increased significantly.

Regional market analysis of the report has backed the study of different regions as an attempt to understand growth pockets that can be beneficial for the market. The regional analysis has import, export, and other processes covered. Players who are getting involved in the market for a better growth are looking for these growth pockets to capitalize on the opportunities provided and find new scopes for growth. Certain countries have been tracked in detail to monitor them closely as they can be major markets in the coming years. Benefits like better infrastructure, cost-effective labor, access to raw materials, they offer have become luring factors for many market players and they want to expand their business to these regions to increase their profit margin.

If you have any special requirements about Male Hypogonadism Therapy Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-male-hypogonadism-therapy-market-size-status-and-forecast-2020-2026?utm_source=farmersledger&utm_medium=39

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read this article:
Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis...

New data from phase 3 clinical trials provide further evidence supporting the safety and effectiveness of the first-to-market oral testosterone undecanoate treatment for hypogonadism (Jatenzo), reported Stanton Honig, MD.

Honig presented results for secondary end points from 2 randomized studies comparing the lipoprotein-coated testosterone undecanoate formulation with topical testosterone treatments showing that both the oral and gel products were associated with statistically significant improvements in psychosocial well-being and bone and body composition parameters. Safety analyses showed the oral testosterone undecanoate was associated with a modest increase in blood pressure, which was slightly higher in men with hypertension at study entry than in men with normal blood pressure and that neither the oral nor gel testosterones had any significant effect on liver function test results.

This novel formulation of testosterone undecanoate is a first-in-class oral testosterone replacement that does not have liver issues, said Honig, professor of clinical urology and director, Mens Health, Yale University School of Medicine, New Haven, Connecticut.

Taken twice daily, it provides hypogonadal men with total testosterone concentrations in the mid-eugonadal range. Its safety profile is generally consistent with injectable and topical testosterone preparations, although the product labeling for oral testosterone undecanoate includes a black box warning about the potential for increased blood pressure. The data collected in the oral testosterone undecanoate studies underscore the need to check blood pressure at some point in men who are started on this therapy, especially those who are hypertensive at baseline.

The 2 trials comprised a 4-month study and a 12-month investigation. Eligibility criteria were similar in the 2 trials. Men ages 18 to 65 years (to 75 years in the 12-month study) were included if they had hypogonadism (serum testosterone <300 ng/dL on 2 morning samples approximately 7 days apart), had signs and symptoms consistent with hypogonadism, and were either naive to or underwent washout from testosterone therapy.

The 4-month study randomized 222 men 3:1 to oral testosterone undecanoate 237 mg twice daily or once-daily topical testosterone solution. A total of 325 men were randomized 1:1 to oral testosterone undecanoate 200 mg twice daily or topical testosterone gel in the 12-month trial. Dose adjustments were allowed based on serum testosterone levels.

The 4 treatment groups were similar with respect to demographics and clinical characteristics in terms of baseline age, body mass index, comorbidities (prediabetes, diabetes, and hypertension), and mean baseline testosterone levels. Time-weighted average testosterone concentration increased to reach mid-eugonadal levels in all 4 treatment groups, with values ranging from 425 ng/dL to 524 ng/dL across all 4 study groups.

Data on psychosocial well-being were collected in both trials using the Psychosexual Daily Questionnaire. Results showed statistically significant improvements from baseline to study completion in mood, sexual desire, weekly sexual activity, and sexual energy with and without a partner with both the oral and topical treatments, Honig reported.

General well-being was evaluated in the 12-month study using the 36-Item Short Form Health Survey questionnaire. In the individual domains, statistically significant improvements were achieved in both the oral testosterone undecanoate and testosterone gel group and occurred in physical functioning, physical and emotional role limitation, social functioning, and bodily pain.

Changes in body composition parameters were also investigated in the 12-month study. The results for the oral testosterone undecanoate group showed spine bone mineral density, hip bone mineral density, lean body mass, and fat mass all improved significantly from baseline at 6 months with further improvements achieved at month 12.

Both the oral testosterone undecanoate and topical testosterone treatments were associated with minimal increases in serum prostate-specific antigen. Overall, the oral and topical treatments were associated with an increase of hematocrit in approximately 5% to 6% of patients.

Importantly, there were no clinical events associated with the hematocrit increases in the oral testosterone undecanoate or the testosterone gel group, nor did any patient discontinue treatment because of elevated hematocrit, Honig said.

Changes in blood pressure were followed using ambulatory monitoring. Among men treated with oral testosterone undecanoate, mean changes in 24-hour systolic and diastolic blood pressure were approximately 5 mm Hg and 2.5 mm Hg, respectively. Comparisons between men with and without hypertension at baseline showed that the average change was slightly higher in the hypertensive group.

Honig said, It is unclear whether the blood pressure rise is just for oral testosterone undecanoate or a general class effect, as it has been seen with subcutaneous testosterone preparations as well. Most importantly, both oral testosterone undecanoate and topical gel groups showed no significant changes in liver enzyme measurements over a 12-month period.

Disclosure: Honig is a consultant to Clarus Therapeutics and Endo.

Originally posted here:
QOL and body composition benefits seen with novel oral T treatment - Urology Times

A novel lymphatically delivered oral testosterone undecanoate (Tlando) is a fixed-dose, well-tolerated, and effective treatment for hypogonadism with liver health benefits that clearly differentiate it from the potentially hepatotoxic oral methyltestosterone, reported Irwin Goldstein, MD, at the American Urological Association 2020 Virtual Experience.

This innovative product has exciting, paradigm-shifting potential for treating men with low testosterone, said Goldstein, director of Sexual Medicine at Alvarado Hospital in San Diego, California, and clinical professor of surgery at the University of California San Diego.

It offers the opportunity to provide safe, effective, and well-tolerated testosterone replacement through the oral route that is the generally preferred method for medication administration. In addition, available data indicate that it not only avoids the adverse hepatic effects that have historically limited use of oral testosterone, but it improves markers of nonalcoholic fatty liver disease [NAFLD] that is a serious and prevalent condition. Low testosterone (ie, hypogonadism) is common in males with NAFLD.

Methyltestosterone is prone to cause liver toxicity with oral ingestion because it is directly transported to the liver through the portal vein, Goldstein said. In contrast, the lymphatically delivered oral testosterone undecanoate is a nonmethylated prodrug of endogenous testosterone, found in Tlando, that avoids first-pass metabolism in the liver and enters the systemic circulation via the lymphatics.

The safety and efficacy of Tlando for treating men with low testosterone was investigated in the 1-year SOAR trial that included 210 men who received the investigational product and a control group of 105 patients treated with topical testosterone gel.

Results from SOAR showed that the oral testosterone undecanoate was associated with a significantly greater increase in free testosterone levels compared with the topical product, and it improved key mental and sexual domains, reported Goldstein, who was an investigator in SOAR and an earlier dosing study.

Safety data in the study included measurement of liver enzymes and showed that reductions were consistently achieved in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and -glutamyl transferase among men who had elevated levels of those markers of liver injury at baseline. Rates of normalization for those 4 enzymes ranged from 31% for -glutamyl transferase to 67% for alkaline phosphatase.

40% reduction in liver fat at 4 months

Additional data on the liver effects of the novel testosterone undecanoate product were obtained in a smaller separate trial of men with hypogonadism. Using the objective Magnetic Resonance Imaging Proton Density Fat Fraction technique to measure liver fat percentage, it found that after 4 months, men with NAFLD at baseline achieved an approximately 40% reduction in liver fat. In addition, more than 75% of men who entered the study with NAFLD were considered responders to the oral testosterone undecanoate based on achieving a 30% or greater reduction in the percentage of liver fat.

In addition, the percentage of patients categorized as NAFLD-free rose during the study and nearly doubled by its conclusion, increasing from 34% at baseline to reach 63% at 16 weeks.

Interestingly, the higher the baseline body mass index, the greater the reduction in liver fat achieved with Tlando treatment, and it appears that the improvement in liver fat does not appear to be explained by any decrease in body weight, Goldstein said.

Disclosures: Lipocine Inc provided funding for the study. Goldstein is on the consultant/advisory board of Lipocine Inc, does research for AbbVie Inc and Marius Pharmaceuticals LLC, is on the Clarus Therapeutics, Inc speakers bureau, and receives writing support from Endo International.

See the original post here:
Novel oral testosterone therapy shows liver health benefits - Urology Times

Human chorionic gonadotropin (hCG) hails from the group of gonadotropin hormones and is normally created by the placenta. hCG hormone plays a vital job after the development of the incipient organism, and thus has increased huge footing throughout the years for the treatment of fruitlessness in men and women.

Sample Link Here: https://www.globalinforeports.com/request-sample/1070128

Ascend in the incidence of male hypogonadism among the aged populace is the key factor driving the market development. Likewise, increment in footing picked up by hCG among social insurance experts and patients would enhance the market development. Nonetheless, alerts and admonitions gave by the FDA relating to the symptoms of hCG treatment is anticipated to hamper the market development.

North America was the significant revenue generator in 2017 and is foreseen to keep up its predominance all through the conjecture time frame. This is ascribed to noteworthy increment in occurrence of infertility related issues both in females and male.

Purchase Link Here: https://www.globalinforeports.com/checkout/1070128

See original here:
Rising infertility related issues are boosting the growth of the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Covid-19 Impact on Male Hypogonadism Therapy market. It informs readers about key trends and opportunities in the global Covid-19 Impact on Male Hypogonadism Therapy market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Covid-19 Impact on Male Hypogonadism Therapy market.

Key companies operating in the global Covid-19 Impact on Male Hypogonadism Therapy market include , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD Male Hypogonadism Therapy

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1734929/covid-19-impact-on-global-male-hypogonadism-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Covid-19 Impact on Male Hypogonadism Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Covid-19 Impact on Male Hypogonadism Therapy Market Segment By Type:

, Parenteral, Transdermal, Oral, Other

Global Covid-19 Impact on Male Hypogonadism Therapy Market Segment By Application:

, Hospitals, Drugstores, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Covid-19 Impact on Male Hypogonadism Therapy market.

Key companies operating in the global Covid-19 Impact on Male Hypogonadism Therapy market include , Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD Male Hypogonadism Therapy

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1734929/covid-19-impact-on-global-male-hypogonadism-therapy-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Male Hypogonadism Therapy Revenue1.4 Market Analysis by Type 1.4.1 Global Male Hypogonadism Therapy Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Parenteral 1.4.3 Transdermal 1.4.4 Oral 1.4.5 Others1.5 Market by Application 1.5.1 Global Male Hypogonadism Therapy Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Drugstores 1.5.4 Others1.6 Coronavirus Disease 2019 (Covid-19): Male Hypogonadism Therapy Industry Impact 1.6.1 How the Covid-19 is Affecting the Male Hypogonadism Therapy Industry 1.6.1.1 Male Hypogonadism Therapy Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Male Hypogonadism Therapy Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Male Hypogonadism Therapy Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Male Hypogonadism Therapy Market Perspective (2015-2026)2.2 Male Hypogonadism Therapy Growth Trends by Regions 2.2.1 Male Hypogonadism Therapy Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Male Hypogonadism Therapy Historic Market Share by Regions (2015-2020) 2.2.3 Male Hypogonadism Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Male Hypogonadism Therapy Market Growth Strategy 2.3.6 Primary Interviews with Key Male Hypogonadism Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Male Hypogonadism Therapy Players by Market Size 3.1.1 Global Top Male Hypogonadism Therapy Players by Revenue (2015-2020) 3.1.2 Global Male Hypogonadism Therapy Revenue Market Share by Players (2015-2020) 3.1.3 Global Male Hypogonadism Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Male Hypogonadism Therapy Market Concentration Ratio 3.2.1 Global Male Hypogonadism Therapy Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Male Hypogonadism Therapy Revenue in 20193.3 Male Hypogonadism Therapy Key Players Head office and Area Served3.4 Key Players Male Hypogonadism Therapy Product Solution and Service3.5 Date of Enter into Male Hypogonadism Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Male Hypogonadism Therapy Historic Market Size by Type (2015-2020)4.2 Global Male Hypogonadism Therapy Forecasted Market Size by Type (2021-2026) 5 Male Hypogonadism Therapy Breakdown Data by Application (2015-2026)5.1 Global Male Hypogonadism Therapy Market Size by Application (2015-2020)5.2 Global Male Hypogonadism Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Male Hypogonadism Therapy Market Size (2015-2020)6.2 Male Hypogonadism Therapy Key Players in North America (2019-2020)6.3 North America Male Hypogonadism Therapy Market Size by Type (2015-2020)6.4 North America Male Hypogonadism Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Male Hypogonadism Therapy Market Size (2015-2020)7.2 Male Hypogonadism Therapy Key Players in Europe (2019-2020)7.3 Europe Male Hypogonadism Therapy Market Size by Type (2015-2020)7.4 Europe Male Hypogonadism Therapy Market Size by Application (2015-2020) 8 China8.1 China Male Hypogonadism Therapy Market Size (2015-2020)8.2 Male Hypogonadism Therapy Key Players in China (2019-2020)8.3 China Male Hypogonadism Therapy Market Size by Type (2015-2020)8.4 China Male Hypogonadism Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Male Hypogonadism Therapy Market Size (2015-2020)9.2 Male Hypogonadism Therapy Key Players in Japan (2019-2020)9.3 Japan Male Hypogonadism Therapy Market Size by Type (2015-2020)9.4 Japan Male Hypogonadism Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Male Hypogonadism Therapy Market Size (2015-2020)10.2 Male Hypogonadism Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Male Hypogonadism Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Male Hypogonadism Therapy Market Size by Application (2015-2020) 11 India11.1 India Male Hypogonadism Therapy Market Size (2015-2020)11.2 Male Hypogonadism Therapy Key Players in India (2019-2020)11.3 India Male Hypogonadism Therapy Market Size by Type (2015-2020)11.4 India Male Hypogonadism Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Male Hypogonadism Therapy Market Size (2015-2020)12.2 Male Hypogonadism Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Male Hypogonadism Therapy Market Size by Type (2015-2020)12.4 Central & South America Male Hypogonadism Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Eli Lilly 13.1.1 Eli Lilly Company Details 13.1.2 Eli Lilly Business Overview and Its Total Revenue 13.1.3 Eli Lilly Male Hypogonadism Therapy Introduction 13.1.4 Eli Lilly Revenue in Male Hypogonadism Therapy Business (2015-2020)) 13.1.5 Eli Lilly Recent Development13.2 Pfizer 13.2.1 Pfizer Company Details 13.2.2 Pfizer Business Overview and Its Total Revenue 13.2.3 Pfizer Male Hypogonadism Therapy Introduction 13.2.4 Pfizer Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.2.5 Pfizer Recent Development13.3 AbbVie 13.3.1 AbbVie Company Details 13.3.2 AbbVie Business Overview and Its Total Revenue 13.3.3 AbbVie Male Hypogonadism Therapy Introduction 13.3.4 AbbVie Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.3.5 AbbVie Recent Development13.4 Novo Nordisk 13.4.1 Novo Nordisk Company Details 13.4.2 Novo Nordisk Business Overview and Its Total Revenue 13.4.3 Novo Nordisk Male Hypogonadism Therapy Introduction 13.4.4 Novo Nordisk Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.4.5 Novo Nordisk Recent Development13.5 Merck KGaA 13.5.1 Merck KGaA Company Details 13.5.2 Merck KGaA Business Overview and Its Total Revenue 13.5.3 Merck KGaA Male Hypogonadism Therapy Introduction 13.5.4 Merck KGaA Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.5.5 Merck KGaA Recent Development13.6 Mylan 13.6.1 Mylan Company Details 13.6.2 Mylan Business Overview and Its Total Revenue 13.6.3 Mylan Male Hypogonadism Therapy Introduction 13.6.4 Mylan Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.6.5 Mylan Recent Development13.7 Bayer 13.7.1 Bayer Company Details 13.7.2 Bayer Business Overview and Its Total Revenue 13.7.3 Bayer Male Hypogonadism Therapy Introduction 13.7.4 Bayer Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.7.5 Bayer Recent Development13.8 Teva 13.8.1 Teva Company Details 13.8.2 Teva Business Overview and Its Total Revenue 13.8.3 Teva Male Hypogonadism Therapy Introduction 13.8.4 Teva Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.8.5 Teva Recent Development13.9 Novartis 13.9.1 Novartis Company Details 13.9.2 Novartis Business Overview and Its Total Revenue 13.9.3 Novartis Male Hypogonadism Therapy Introduction 13.9.4 Novartis Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.9.5 Novartis Recent Development13.10 Abbott 13.10.1 Abbott Company Details 13.10.2 Abbott Business Overview and Its Total Revenue 13.10.3 Abbott Male Hypogonadism Therapy Introduction 13.10.4 Abbott Revenue in Male Hypogonadism Therapy Business (2015-2020) 13.10.5 Abbott Recent Development13.11 Roche 10.11.1 Roche Company Details 10.11.2 Roche Business Overview and Its Total Revenue 10.11.3 Roche Male Hypogonadism Therapy Introduction 10.11.4 Roche Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.11.5 Roche Recent Development13.12 Endo International 10.12.1 Endo International Company Details 10.12.2 Endo International Business Overview and Its Total Revenue 10.12.3 Endo International Male Hypogonadism Therapy Introduction 10.12.4 Endo International Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.12.5 Endo International Recent Development13.13 Ipsen 10.13.1 Ipsen Company Details 10.13.2 Ipsen Business Overview and Its Total Revenue 10.13.3 Ipsen Male Hypogonadism Therapy Introduction 10.13.4 Ipsen Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.13.5 Ipsen Recent Development13.14 ANI Pharmaceuticals 10.14.1 ANI Pharmaceuticals Company Details 10.14.2 ANI Pharmaceuticals Business Overview and Its Total Revenue 10.14.3 ANI Pharmaceuticals Male Hypogonadism Therapy Introduction 10.14.4 ANI Pharmaceuticals Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.14.5 ANI Pharmaceuticals Recent Development13.15 TherapeuticsMD 10.15.1 TherapeuticsMD Company Details 10.15.2 TherapeuticsMD Business Overview and Its Total Revenue 10.15.3 TherapeuticsMD Male Hypogonadism Therapy Introduction 10.15.4 TherapeuticsMD Revenue in Male Hypogonadism Therapy Business (2015-2020) 10.15.5 TherapeuticsMD Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original here:
Male Hypogonadism Therapy Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026 - Weekly Wall

Sarah L. Berga has been appointed as the new chair of the Department of Obstetrics and Gynecology in the Jacobs School of Medicine and Biomedical Sciences at UB. She will also serve as president of UBMD Obstetrics & Gynecology, and medical director of Obstetrics and Gynecology and Maternal Fetal Medicine Program Development for Kaleida Health.

Bergas appointments, which began June 1, were announced by Michael E. Cain, vice president for health sciences and dean of the Jacobs School.

Dr. Berga rapidly emerged as our top candidate possessing the administrative, scientific, clinical, leadership and visionary skills needed to move the department forward, expand the departments basic and clinical research programs to fulfill the Jacobs Schools strategic goals, enhance the excellence of the departments graduate medical education and mentored research training programs, and develop and align a comprehensive clinical program at Kaleida Health and our community, Cain said.

Berga will succeed Vanessa Barnabei, who had served as chair since 2012. Barnabei has accepted a new position at the Jacobs School as associate dean for faculty advancement and development. In this new role, she will work with department chairs and chiefs, senior leaders in the offices of Faculty Affairs, the Medical Education and Education Research Institute, Diversity and Inclusion, Graduate Medical Education, Research Integration and others both within the school and beyond to promote opportunities for faculty scholarly activity, academic promotion, retention and wellness.She will continue in her clinical capacity, seeing patients at UBMD Obstetrics & Gynecology.

Berga comes to UB from the University of Utah School of Medicines Department of Obstetrics and Gynecology, where she served as professor and director of the Division of Reproductive Endocrinology and Infertility for two years.

(Berga) is an accomplished clinician, physician-investigator and educator, Cain said.

In addition, she is a diplomat of the National Board of Medical Examiners, the American Board of Obstetrics and Gynecology and the American Board of Obstetrics and Gynecology Division of Reproductive Endocrinology and Infertility.

I am totally thrilled to be joining the Jacobs School of Medicine and Biomedical Sciences, Kaleida Health and UBMD Obstetrics & Gynecology, Berga said. I was excited to be asked to look at the position; it is an amazing opportunity to build on what has been achieved to date at UB in the Jacobs School and in obstetrics, gynecology and womens health in particular.The new Oishei hospital is magnificent and the partnership with UB presents an unparalleled synergistic opportunity to expand programs, to conduct translational and clinical research, and to educate the next generation of womens health physicians and providers of all types.

Caring for patients through UBMD Obstetrics & Gynecology and Kaleida Health, Berga specializes in reproductive hormones, infertility and stress-induced hypothalamic hypogonadism (amenorrhea). Her clinical interests include in vitro fertilization (IVF), which she will be introducing to the UBMD practice, as well as perimenopause, hormone therapies and polycystic ovary syndrome.

Her research interests include determining the neuroendocrine mechanisms mediating stress-induced reproductive compromise and the impact of sex hormones on brain health in human and monkey models using neuroimaging and delineation of hormonal and cognitive patterns. Her research endeavors have been consistently funded by the National Institutes of Health, research foundations and industry.

Ive always been interested in how mindset attitudes and behaviors influence hormones and reproductive hormones in particular, Berga said.Her current research collaborations include understanding how stress and hormones influence brain and heart health in women.

Berga has authored or co-authored over 150 peer-reviewed scientific articles and written over 85 book chapters. In 2020, she was awarded the DeCherney Society Lifetime Distinguished Service Award by the Society for Reproductive Investigation. She currently serves as an associate editor for Human Reproduction Update. She has served on many NIH grant review committees.

Berga received her bachelors degree from the University of Virginia and her medical degree from the University of Virginia School of Medicine. She completed a residency in obstetrics and gynecology at Harvard Medical School, followed by a fellowship in reproductive endocrinology at University of California, San Diego School of Medicine.

She served as assistant professor, associate professor and professor at the University of Pittsburgh School of Medicine. She has also served as the James Robert McCord Professor and Chair in the Department of Gynecology and Obstetrics, Division of Reproductive Endocrinology and Infertility at the Emory University School of Medicine.

Read more from the original source:
Jacobs School appoints new chair of Obstetrics and Gynecology - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

The global male hypogonadism market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period. Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

Some of the key players of Male Hypogonadism Market:AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli Lilly and Company Ltd., Endo International plc., Merck & Co., Inc., Ferring, Finox Biotech, IBSA Institut Biochimque SA, Laboratoires Genevrier, Teva Pharmaceutical Industries Ltd.

Get Sample Copy of this Report @ https://www.reportsweb.com/inquiry&RW00012659727/sample

Male Hypogonadism Market report provides in-depth statistics and analysis available on the market status of the Male Hypogonadism key players and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the Male Hypogonadism market. It contains the analysis of drivers, challenges, and restraints impacting the industry.

Type Segmentation:Klinefelters Syndrome

Kallmann Syndrome

Pituitary Disorders

Others

DRUG DELIVERY Segmentation:Topical Gels

Injectables

Transdermal Patches

Others

Major Regions play vital role in Male Hypogonadism market are:North America, Europe, China, Japan, Middle East & Africa, India, South America, Others

Get Discount for This Report @ https://www.reportsweb.com/inquiry&RW00012659727/discount

Research objectives

To study and analyze the global Die Cutting Machines consumption (value & volume) by key regions/countries, type and application, history data, and forecast.

To understand the structure of Die Cutting Machines market by identifying its various subsegments.

Focuses on the key global Die Cutting Machines manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Die Cutting Machines with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Die Cutting Machines submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Fundamentals of Table of Content:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface

Chapter 4 Market Landscape

Chapter 5 Market Trend Analysis

Chapter 6 Industry Chain Analysis

Chapter 7 Latest Market Dynamics

Chapter 8 Trading Analysis

Chapter 9 Historical and Current Interposer in North America

Continue for TOC

Purchase This Report @ https://www.reportsweb.com/inquiry&RW00012659727/buying

About ReportsWeb:ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Excerpt from:
Demanded Report on Male Hypogonadism Market Analysis Forecast with Leading Key Players: AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli...

Analysis of the Global Male Hypogonadism Market

A recently published market report on the Male Hypogonadism market highlights the pitfalls that companies might come across due to the unprecedented outbreak of COVID-19 (Coronavirus). Buyers can request comprehensive market analysis of Coronavirus and its impact on the Male Hypogonadism market to mitigate revenue losses.

This market research report on the Male Hypogonadism market published by Male Hypogonadism derives current insights about the competitive landscape of the Male Hypogonadism market. Further, the report unfolds detailed analysis of different segments of the Male Hypogonadism market and offers a thorough understanding of the growth potential of each market segment over the assessment period (20XX-20XX).

According to the analysts at Male Hypogonadism , the Male Hypogonadism market is predicted to register a CAGR growth of ~XX% during the assessment and reach a value of ~US$ XX by the end of 20XX. The report analyzes the micro and macro-economic factors that are projected to influence the growth of the Male Hypogonadism market in the coming decade.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2677738&source=atm

Key Insights Highlighted in the Report

Segmentation of the Male Hypogonadism Market

The presented report elaborate on the Male Hypogonadism market into different segments and ponders over the current and future business potentials of each segment. The report showcases the year-on-year growth of each segment and ponders upon the different factors that are likely to influence the growth of each market segment.

The various segments of the Male Hypogonadism market explained in the report include:

Key market playersMajor competitors identified in this market include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd., Finox Biotech, Teva Pharmaceutical Industries Ltd., Bayer AG, IBSA Institut Biochimque, etc.

Based on the Region:Asia-Pacific (China, Japan, South Korea, India and ASEAN)North America (US and Canada)Europe (Germany, France, UK and Italy)Rest of World (Latin America, Middle East & Africa)

Based on the Type:Testosterone Replacement TherapyGonadotropin-Releasing Hormones Therapy

Based on the Application:Kallmann SyndromeKlinefelters SyndromePituitary DisordersOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2677738&source=atm

Important doubts related to the Male Hypogonadism market clarified in the report:

Why Choose Male Hypogonadism

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2677738&licType=S&source=atm

Follow this link:
COVID-19: Responding to the business impacts of Global Male Hypogonadism Market : Current Trends and Future Estimations to Elucidate Imminent...

QY Research as of late produced a research report titled, Transdermal Testosterone . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Transdermal Testosterone market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key companies that are operating in the global Transdermal Testosterone market are: , AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddys Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1536918/global-transdermal-testosterone-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of the market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Transdermal Testosterone Market Segment By Type:

, Gel, Patch, Solution

Global Transdermal Testosterone Market Segment By Application:

, Primary hypogonadism, Hypogonadotropic hypogonadism, Late-onset hypogonadism

Competitive Landscape

The report incorporates various key players and producers working in the local and worldwide market. This segment shows the procedures received by players in the market to remain ahead in the challenge. New patterns and its reception by players assist readers with understanding the elements of the business and how it very well may be utilized to their own benefit. The readers can likewise recognize the strides of players to comprehend the global market better.

Key companies operating in the global Transdermal Testosterone market include , AbbVie, Teva, Perrigo, Endo Pharmaceuticals, Acerus Pharmaceuticals, Lupin, Dr. Reddys Laboratories, Upsher-Smith Laboratories, Allergan, Cipla Inc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1536918/global-transdermal-testosterone-market

TOC

Table of Contents 1 Transdermal Testosterone Market Overview1.1 Transdermal Testosterone Product Overview1.2 Transdermal Testosterone Market Segment by Type1.2.1 Gel1.2.2 Patch1.2.3 Solution1.3 Global Transdermal Testosterone Market Size by Type (2015-2026)1.3.1 Global Transdermal Testosterone Market Size Overview by Type (2015-2026)1.3.2 Global Transdermal Testosterone Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Transdermal Testosterone Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Transdermal Testosterone Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Transdermal Testosterone Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Transdermal Testosterone Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Transdermal Testosterone Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Transdermal Testosterone Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Transdermal Testosterone Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.2 Europe Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.4 Latin America Transdermal Testosterone Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Transdermal Testosterone Sales Breakdown by Type (2015-2026) 2 Global Transdermal Testosterone Market Competition by Company2.1 Global Top Players by Transdermal Testosterone Sales (2015-2020)2.2 Global Top Players by Transdermal Testosterone Revenue (2015-2020)2.3 Global Top Players Transdermal Testosterone Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Transdermal Testosterone Manufacturing Base Distribution, Sales Area, Product Type2.5 Transdermal Testosterone Market Competitive Situation and Trends2.5.1 Transdermal Testosterone Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Transdermal Testosterone Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transdermal Testosterone as of 2019)2.7 Date of Key Manufacturers Enter into Transdermal Testosterone Market2.8 Key Manufacturers Transdermal Testosterone Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Transdermal Testosterone Status and Outlook by Region (2015-2026)3.1 Global Transdermal Testosterone Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Transdermal Testosterone Market Size Market Share by Region (2015-2020)3.2.1 Global Transdermal Testosterone Sales Market Share by Region (2015-2020)3.2.2 Global Transdermal Testosterone Revenue Market Share by Region (2015-2020)3.2.3 Global Transdermal Testosterone Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Transdermal Testosterone Market Size Market Share by Region (2021-2026)3.3.1 Global Transdermal Testosterone Sales Market Share by Region (2021-2026)3.3.2 Global Transdermal Testosterone Revenue Market Share by Region (2021-2026)3.3.3 Global Transdermal Testosterone Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Transdermal Testosterone Market Size YoY Growth (2015-2026)3.4.1 North America Transdermal Testosterone Revenue YoY Growth (2015-2026)3.4.2 North America Transdermal Testosterone Sales YoY Growth (2015-2026)3.5 Asia-Pacific Transdermal Testosterone Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Transdermal Testosterone Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Transdermal Testosterone Sales YoY Growth (2015-2026)3.6 Europe Transdermal Testosterone Market Size YoY Growth (2015-2026)3.6.1 Europe Transdermal Testosterone Revenue YoY Growth (2015-2026)3.6.2 Europe Transdermal Testosterone Sales YoY Growth (2015-2026)3.7 Latin America Transdermal Testosterone Market Size YoY Growth (2015-2026)3.7.1 Latin America Transdermal Testosterone Revenue YoY Growth (2015-2026)3.7.2 Latin America Transdermal Testosterone Sales YoY Growth (2015-2026)3.8 Middle East and Africa Transdermal Testosterone Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Transdermal Testosterone Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Transdermal Testosterone Sales YoY Growth (2015-2026) 4 Global Transdermal Testosterone by Application4.1 Transdermal Testosterone Segment by Application4.1.1 Primary hypogonadism4.1.2 Hypogonadotropic hypogonadism4.1.3 Late-onset hypogonadism4.2 Global Transdermal Testosterone Sales by Application: 2015 VS 2020 VS 20264.3 Global Transdermal Testosterone Historic Sales by Application (2015-2020)4.4 Global Transdermal Testosterone Forecasted Sales by Application (2021-2026)4.5 Key Regions Transdermal Testosterone Market Size by Application4.5.1 North America Transdermal Testosterone by Application4.5.2 Europe Transdermal Testosterone by Application4.5.3 Asia-Pacific Transdermal Testosterone by Application4.5.4 Latin America Transdermal Testosterone by Application4.5.5 Middle East and Africa Transdermal Testosterone by Application 5 North America Transdermal Testosterone Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Transdermal Testosterone Sales Market Share by Country (2015-2020)5.1.2 North America Transdermal Testosterone Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Transdermal Testosterone Sales Market Share by Country (2021-2026)5.2.2 North America Transdermal Testosterone Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Transdermal Testosterone Market Size YoY Growth (2015-2026)5.3.2 Canada Transdermal Testosterone Market Size YoY Growth (2015-2026) 6 Europe Transdermal Testosterone Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Transdermal Testosterone Sales Market Share by Country (2015-2020)6.1.2 Europe Transdermal Testosterone Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Transdermal Testosterone Sales Market Share by Country (2021-2026)6.2.2 Europe Transdermal Testosterone Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.2 France Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.3 U.K. Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.4 Italy Transdermal Testosterone Market Size YoY Growth (2015-2026)6.3.5 Russia Transdermal Testosterone Market Size YoY Growth (2015-2026) 7 Asia-Pacific Transdermal Testosterone Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Transdermal Testosterone Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Transdermal Testosterone Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Transdermal Testosterone Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Transdermal Testosterone Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.2 Japan Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.3 South Korea Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.4 India Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.5 Australia Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.6 Taiwan Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.7 Indonesia Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.8 Thailand Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.9 Malaysia Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.10 Philippines Transdermal Testosterone Market Size YoY Growth (2015-2026)7.3.11 Vietnam Transdermal Testosterone Market Size YoY Growth (2015-2026) 8 Latin America Transdermal Testosterone Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Transdermal Testosterone Sales Market Share by Country (2015-2020)8.1.2 Latin America Transdermal Testosterone Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Transdermal Testosterone Sales Market Share by Country (2021-2026)8.2.2 Latin America Transdermal Testosterone Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Transdermal Testosterone Market Size YoY Growth (2015-2026)8.3.2 Brazil Transdermal Testosterone Market Size YoY Growth (2015-2026)8.3.3 Argentina Transdermal Testosterone Market Size YoY Growth (2015-2026) 9 Middle East and Africa Transdermal Testosterone Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Transdermal Testosterone Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Transdermal Testosterone Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Transdermal Testosterone Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Transdermal Testosterone Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Transdermal Testosterone Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Transdermal Testosterone Market Size YoY Growth (2015-2026)9.3.3 U.A.E Transdermal Testosterone Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Transdermal Testosterone Business10.1 AbbVie10.1.1 AbbVie Corporation Information10.1.2 AbbVie Description, Business Overview and Total Revenue10.1.3 AbbVie Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.1.4 AbbVie Transdermal Testosterone Products Offered10.1.5 AbbVie Recent Development10.2 Teva10.2.1 Teva Corporation Information10.2.2 Teva Description, Business Overview and Total Revenue10.2.3 Teva Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.2.5 Teva Recent Development10.3 Perrigo10.3.1 Perrigo Corporation Information10.3.2 Perrigo Description, Business Overview and Total Revenue10.3.3 Perrigo Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.3.4 Perrigo Transdermal Testosterone Products Offered10.3.5 Perrigo Recent Development10.4 Endo Pharmaceuticals10.4.1 Endo Pharmaceuticals Corporation Information10.4.2 Endo Pharmaceuticals Description, Business Overview and Total Revenue10.4.3 Endo Pharmaceuticals Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.4.4 Endo Pharmaceuticals Transdermal Testosterone Products Offered10.4.5 Endo Pharmaceuticals Recent Development10.5 Acerus Pharmaceuticals10.5.1 Acerus Pharmaceuticals Corporation Information10.5.2 Acerus Pharmaceuticals Description, Business Overview and Total Revenue10.5.3 Acerus Pharmaceuticals Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.5.4 Acerus Pharmaceuticals Transdermal Testosterone Products Offered10.5.5 Acerus Pharmaceuticals Recent Development10.6 Lupin10.6.1 Lupin Corporation Information10.6.2 Lupin Description, Business Overview and Total Revenue10.6.3 Lupin Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.6.4 Lupin Transdermal Testosterone Products Offered10.6.5 Lupin Recent Development10.7 Dr. Reddys Laboratories10.7.1 Dr. Reddys Laboratories Corporation Information10.7.2 Dr. Reddys Laboratories Description, Business Overview and Total Revenue10.7.3 Dr. Reddys Laboratories Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.7.4 Dr. Reddys Laboratories Transdermal Testosterone Products Offered10.7.5 Dr. Reddys Laboratories Recent Development10.8 Upsher-Smith Laboratories10.8.1 Upsher-Smith Laboratories Corporation Information10.8.2 Upsher-Smith Laboratories Description, Business Overview and Total Revenue10.8.3 Upsher-Smith Laboratories Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.8.4 Upsher-Smith Laboratories Transdermal Testosterone Products Offered10.8.5 Upsher-Smith Laboratories Recent Development10.9 Allergan10.9.1 Allergan Corporation Information10.9.2 Allergan Description, Business Overview and Total Revenue10.9.3 Allergan Transdermal Testosterone Sales, Revenue and Gross Margin (2015-2020)10.9.4 Allergan Transdermal Testosterone Products Offered10.9.5 Allergan Recent Development10.10 Cipla Inc.10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Transdermal Testosterone Product Category, Application and Specification10.10.3 Cipla Inc. Transdermal Testosterone Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Cipla Inc. Recent Development 11 Transdermal Testosterone Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Transdermal Testosterone Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Transdermal Testosterone Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Transdermal Testosterone Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| - Jewish Life News

DailyMailreports that a team of Canadian researchers have discovered a new sex hormone in zebrafish. They say this discovery could lead to developing better fertility treatment options for humans.

The researchers successfully restored partial sexual function in genetically mutated zebrafish with a single injection. In their trial, the jab was able to enhance further the ability of the female fish to ovulate and lay her eggs.

The fish possessed about 70% genes similar to humans, which makes it the perfect lab models. According to researchers, the key to the process is a small-like-molecule produced by the fish. Moreover, this molecule is found in other animals and humans as well.

According to Vance Trudeau, the senior author of the study, they mutated two related genes and analyzed their effects on the zebrafish's sexual function. Trudeau is a Professor of Neuroendocrinology at the University of Ottawa, Canada.

Additionally, he said that they used genetically modified fish to search for other factors that could improve sexual function. The researchers looked for clues leaning toward either increased spawning in cultured fish species or helping with the search for new infertility treatments for humans.

The findings of the research were published in Proceedings of the National Academy of Sciences.

Read Also: Men with Hypogonadism Leading to Low Testosterone Levels are More Likely to Die From the Coronavirus, Study Finds

Professor Trudeau and his co-author Kim Mitchell had discovered new functions that facilitate how males and females interact while mating when they initially started studying the effects of gene mutations in zebrafish.

Using gene technology developed at the Chinese Academy of Sciences, in Wuhan, China, the researchers were able to mutate two related genes under the name secretogranin-2. It encodes the protein with the same name.

Trudeau said that the first step of their experiments was to perform the gene editing to reduce the zebrafish's sexual behaviour. Furthermore, they changed the secretogranin-2 genes through specific mutations. The authors of the study found that it significantly affected the ability of females and males to breed.

According to Trudeau, it severely reduced their sexual behaviour. At first, the fish appeared normal. However, when both sexes were put together, they completely ignored each other. He explained how normally the male and female fish would engage in a 'courtship ritual' in which the male would chase the female.

Generally after the courtship, the female dispenses her eggs to the water, and the male fertilizes them. However, in a sample of gene-edited zebrafish couples used in the study, the researchers found only one in ten were able to spawn.

The experiments showed that the fish carrying the delivered mutations were capable of producing sperm and eggs, but were dreadful at mating. According to Trudeau, it was the first evidence that showed the mutation of genes leading to the disruption of sexual behaviour in animals.

For the experiment's second stage, the researchers used a fragment of secretogranin-2 in an attempt to reverse the seeming incapacity to mate. The team was able to partially restore sexual function by a single injection of the secretoneurin peptideinto the fish's body.

The researchers revealed new genes that can determine reproduction. Furthermore, the secretoneurin peptide itself has been classified as a new hormone with possible connotations for future fertility research.

According to Trudeau, the large secretogranin-2 genes could produce several other hormone-like peptides with functions still left to be discovered. He added that it would be exciting to explore the subject in future projects further.

Also Read: COVID-19 Male Patients to Receive Female Sex Hormones Estrogen and Progesterone To See if They Could Help Reduce Severity

The rest is here:
Scientists Discover New Sexual Hormone that Could Offer Better Fertility Treatments - Science Times